Digital Library
Close Browse articles from a journal
     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             35 results found
no title author magazine year volume issue page(s) type
1 A multi-cancer detection test: focus on the positive predictive value Fiala, C.

31 9 p. 1267-1268
article
2 Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients Nakamura, Y.

31 9 p. 1198-1206
article
3 Aspirin to prevent gastrointestinal cancer – but recent trial data do not fit Jacobsen, A.P.

31 9 p. 1262-1263
article
4 Characterization of on-target adverse events caused by TRK inhibitor therapy Liu, D.

31 9 p. 1207-1215
article
5 Comment on ‘Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA’ by M. C. Liu et al. Taylor, W.C.

31 9 p. 1266-1267
article
6 Corrigendum to ‘Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study’ Pagès, F.

31 9 p. 1276
article
7 Editorial Board
31 9 p. x
article
8 Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial McMillan, A.K.

31 9 p. 1251-1259
article
9 GEP-NET: Knowledge gaps in the recent ESMO Guidelines Jain, A.

31 9 p. 1260-1261
article
10 Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean? Sharifi, Nima

31 9 p. 1103-1105
article
11 HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies Khalaf, D.J.

31 9 p. 1186-1197
article
12 Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial Barcenas, C.H.

31 9 p. 1223-1230
article
13 Patients should be the tipping point of individualizing breast cancer surgery: Commentary on ‘Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges’ Heil, J.

31 9 p. 1264
article
14 PD-1 blockade in Japanese patients with acral lentiginous melanoma Shoushtari, A.N.

31 9 p. 1106-1108
article
15 Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases Metzger Filho, O.

31 9 p. 1231-1239
article
16 Prognostic gene expression signature for high-grade serous ovarian cancer Millstein, J.

31 9 p. 1240-1250
article
17 Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † Parker, C.

31 9 p. 1119-1134
article
18 Reaching out beyond first-line treatments in advanced biliary tract cancers Lamarca, A.

31 9 p. 1099-1102
article
19 Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC) Pentheroudakis, G.

31 9 p. 1265-1266
article
20 Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial Demols, A.

31 9 p. 1169-1177
article
21 Reply to ‘Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?’ by Evesque et al. Holch, J.W.

31 9 p. 1261-1262
article
22 Reply to the Letter to the Editor ‘Aspirin to prevent gastrointestinal cancer – but recent trial data don't fit’ by Jacobsen and colleagues Bosetti, C.

31 9 p. 1263
article
23 Response to W.C. Taylor, and C. Fiala and E.P. Diamandis Liu, M.C.

31 9 p. 1268-1270
article
24 Table of Contents
31 9 p. ii-iv
article
25 The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer Mauri, G.

31 9 p. 1135-1147
article
26 The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians Subbiah, V.

31 9 p. 1115-1118
article
27 The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No Prasad, V.

31 9 p. 1112-1114
article
28 The forefront of ovarian cancer therapy: update on PARP inhibitors Mirza, M.R.

31 9 p. 1148-1159
article
29 Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis Doms, J.

31 9 p. 1273-1275
article
30 Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype Lu, C.

31 9 p. 1178-1185
article
31 Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer Roda, D.

31 9 p. 1097-1098
article
32 Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study ✰ Van Cutsem, E.

31 9 p. 1160-1168
article
33 TRK inhibitors: managing on-target toxicities Lim, J.S.J.

31 9 p. 1109-1111
article
34 Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo Karn, T.

31 9 p. 1216-1222
article
35 Unintended on-target chromosomal instability following CRISPR/Cas9 single gene targeting Przewrocka, J.

31 9 p. 1270-1273
article
                             35 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands